https://caselaw.findlaw.com/summary/opinion/us-federal-circuit/2018/09/10/284212.html
Content Reproduced verbatim from the Website of FindLaw, A Thomson Reuters Business, as permitted under their RSS FEEDS, Terms of Use.
Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., 17-2078
Affirmed that a pharmaceutical company’s patent claims in a multiple sclerosis drug were invalid for obviousness. Several competitors seeking to market a generic version of the same drug raised the issue of obviousness when the company sued them for infringement. In a 2-1 decision, the Federal Circuit affirmed that the patent claims in question were invalid.
Appellate Information
- Decided
- Published 2018/09/10
Judges
Court
- United States Federal Circuit